Bausch Health Companies Inc. Deferred Income Tax Expense (Benefit)
Bausch Health Companies Inc. (BHC) reported Deferred Income Tax Expense (Benefit) of $132.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-19
- Bausch Health Companies Inc. deferred income tax expense (benefit) for the quarter ending 2011-12-31 was -$140.35M.
- Bausch Health Companies Inc. deferred income tax expense (benefit) for the quarter ending 2011-09-30 was -$38.60M, a 164.88% decline year-over-year.
- Bausch Health Companies Inc. deferred income tax expense (benefit) for the quarter ending 2011-06-30 was -$18.72M, a 2774.86% decline year-over-year.
- Bausch Health Companies Inc. deferred income tax expense (benefit) for the quarter ending 2011-03-31 was -$19.77M, a 559.84% decline year-over-year.
- Bausch Health Companies Inc. deferred income tax expense (benefit) for fiscal 2025 was $132.00M, a 91.30% increase from fiscal 2024.
- Bausch Health Companies Inc. deferred income tax expense (benefit) for fiscal 2024 was $69.00M, a 1050.00% increase from fiscal 2023.
- Bausch Health Companies Inc. deferred income tax expense (benefit) for fiscal 2023 was $6.00M.
- Bausch Health Companies Inc. deferred income tax expense (benefit) for fiscal 2022 was -$188.00M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $132.00M 10-K · filed 2026-02-19 | ||||
| 2024-12-31 | $69.00M 10-K · filed 2026-02-19 | ||||
| 2023-12-31 | $6.00M 10-K · filed 2026-02-19 | ||||
| 2022-12-31 | -$188.00M 10-K · filed 2025-02-20 | ||||
| 2021-12-31 | -$36.00M 10-K · filed 2024-02-22 | ||||
| 2020-12-31 | -$599.00M 10-K · filed 2023-02-23 | ||||
| 2019-12-31 | -$182.00M 8-K · filed 2022-05-11 | ||||
| 2018-12-31 | -$337.00M 8-K · filed 2021-05-04 | ||||
| 2017-12-31 | -$4.31B 10-K · filed 2020-02-19 | ||||
| 2016-12-31 | -$268.00M 10-K · filed 2019-02-20 | ||||
| 2015-12-31 | $56.00M 8-K · filed 2018-08-10 | $55.60M 10-K · filed 2016-04-29 | |||
| 2014-12-31 | $23.00M 10-K · filed 2017-03-01 | $29.70M 10-K · filed 2015-02-25 | |||
| 2013-12-31 | -$534.20M 10-K · filed 2016-04-29 | -$534.20M 10-K · filed 2014-02-28 | |||
| 2012-12-31 | -$341.70M 10-K · filed 2015-02-25 | -$341.73M 10-K · filed 2013-02-28 | |||
| 2011-12-31 | -$140.35M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | -$178.95M derived: sum of 2 quarters · filed 2014-02-28 | -$197.68M derived: sum of 3 quarters · filed 2014-02-28 | -$217.45M 10-K · filed 2014-02-28 | |
| 2011-09-30 | -$38.60M 10-Q · filed 2011-11-04 | -$57.33M derived: sum of 2 quarters · filed 2011-11-04 | -$77.10M 10-Q · filed 2011-11-04 | -$197.00M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2011-06-30 | -$18.72M 10-Q · filed 2011-08-08 | -$38.50M 10-Q · filed 2011-08-08 | -$158.40M derived: sum of 3 quarters · filed 2013-02-28 | -$98.90M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2011-03-31 | -$19.77M 10-Q · filed 2011-05-10 | -$139.68M derived: sum of 2 quarters · filed 2013-02-28 | -$80.18M derived: sum of 3 quarters · filed 2013-02-28 | -$79.48M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2010-12-31 | -$119.90M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$60.40M derived: sum of 2 quarters · filed 2013-02-28 | -$59.70M derived: sum of 3 quarters · filed 2013-02-28 | -$55.40M 10-K · filed 2013-02-28 | |
| 2010-09-30 | $59.50M 10-Q · filed 2011-11-04 | $60.20M derived: sum of 2 quarters · filed 2011-11-04 | $64.50M 10-Q · filed 2011-11-04 | $36.50M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2010-06-30 | $700.00K 10-Q · filed 2011-08-08 | $5.00M 10-Q · filed 2011-08-08 | -$23.00M derived: sum of 3 quarters · filed 2012-02-29 | -$19.20M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2010-03-31 | $4.30M 10-Q · filed 2011-05-10 | -$23.70M derived: sum of 2 quarters · filed 2012-02-29 | -$19.90M derived: sum of 3 quarters · filed 2012-02-29 | -$19.50M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2009-12-31 | -$28.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$24.20M derived: sum of 2 quarters · filed 2012-02-29 | -$23.80M derived: sum of 3 quarters · filed 2012-02-29 | -$16.00M 10-K · filed 2012-02-29 | |
| 2009-09-30 | $3.80M 10-Q · filed 2010-11-05 | $4.20M derived: sum of 2 quarters · filed 2010-11-05 | $12.00M 10-Q · filed 2010-11-05 | ||
| 2009-06-30 | $400.00K 10-Q · filed 2010-08-06 | $8.20M 10-Q · filed 2010-08-06 | |||
| 2008-12-31 | -$90.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |